GlassScriptPhysician profile
Steven M Dean
NPI 1518958735
$1,728.83
in general payments reported to CMS, 2019-2025
25 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $35.79 · 2022: $485 · 2023: $309 · 2024: $263 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $391.74 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $200.00 | 2023-2025 | Myfembree |
| Acella Pharmaceuticals, LLC | $138.31 | 2019-2024 | NP Thyroid 60 |
| Amgen INC. | $126.18 | 2019-2025 | Evenity, Prolia |
| Myovant Sciences INC. | $120.24 | 2022 | |
| Astellas Pharma US INC | $96.66 | 2023-2025 | Veozah |
| Intuitive Surgical, INC. | $86.65 | 2019 | |
| Exact Sciences Corporation | $64.70 | 2024-2025 | Cologuard Collection Kit |
| Myriad Women'S Health, INC. | $62.59 | 2023 | Myrisk |
| Pfizer INC. | $61.26 | 2022-2024 | |
| Channel Medsystems, INC. | $55.59 | 2025 | |
| Conmed Corporation | $48.23 | 2022 | |
| Coopersurgical, INC. | $40.24 | 2022-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $33.75 | 2019-2022 | |
| Ibsa Pharma INC. | $29.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $27.18 | 2023 | |
| Gynesonics, INC. | $22.44 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertical Pharmaceuticals, LLC | $18.94 | 2019 | |
| Ascend Therapeutics US, LLC | $16.07 | 2022 | |
| Millicent US INC | $15.97 | 2024 | Intrarosa, Femring |
| Scynexis, INC. | $15.50 | 2022 | |
| Currax Pharmaceuticals LLC | $15.31 | 2024 | Contrave |
| Novo Nordisk INC | $14.25 | 2023 | Wegovy |
| Amag Pharmaceuticals, INC. | $14.11 | 2019 | |
| Acessa Health INC. | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.